Study reveals striking similarities in both behaviors and neuroanatomical changes between people with schizophrenia and behavioral-variant frontotemporal dementia.
Microglia that express the Alzheimer's associated APOE4 genetic variant are unable to effectively metabolize lipids. This causes lipids to build up, promoting inflammation and preventing effective neurotransmission.
A newly developed novel fusion protein drug efficiently eliminates amyloid beta via an entirely different mechanism than amyloid-beta antibody-based immunotherapy.
The effects of COVID-19 infection on neurological health are becoming more apparent. A new study reveals COVID-19 can predispose people to irreversible neurological conditions, accelerate brain aging, and increase the risk of stroke and brain bleeds.
Researchers identified a pathway that begins in the gut and ends with a pro-inflammatory protein in the brain that appears to contribute to the development and progression of Alzheimer's disease.
A new collection of articles explores mapping brain overexcitability that underpins the dysregulation of vigilance, sleep-wake cycles, and validating effective biomarkers for Alzheimer's disease.
Using CRISPR gene editing, researchers were able to control microglia and reverse their toxic state associated with Alzheimer's disease, and put them back on track.
A1R-CT, a novel peptide that binds to neurabin, can be administered via a nasal spray and holds the potential to interrupt uncontrollable brain activity associated with TBI, stroke, epilepsy, and Alzheimer's disease.
DDT exposure causes sodium channels to remain open, leading to increased neural firing and an increased release of amyloid beta peptide. Blocking the channels with tetrodotoxin reduces the toxic amyloid protein by increasing the production of the amyloid precursor protein.
Increasing neurogenesis by deleting the Bax gene in mouse models of Alzheimer's improved the animals' performance in tests measuring spatial recognition and contextual memory.